Event Type
Disclosure
Mandatory
Variant
8-K
. Item 2.01. Completion of Acquisition or Disposition of Assets Share Exchange Agreement On November 21, 2025, Lixte Biotechnology Holdings, Inc., a Delaware co
and Item 5.03 of this Form 8-K is hereby incorporated by reference into this Item 3.02 in its entirety. The Series C Preferred Stock has not been registered und
of this Form 8-K but not otherwise defined have the meaning set forth in the Certificate of Designation. Item 7.01 Regulation FD Disclosure On November 25, 2025
Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed herewith. Exhibit Number Description 3.1 Certificate of Designation of Preferen